GSK's Respiratory Syncytial Virus Vaccine Given Together With Shingles Shot Shows Non-Inferior Immune Response In Older Adults
GSK plc (NYSE:GSK) released topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of Arexvy (Respiratory Syncytial Virus Vaccine) when co-administered with Shingrix (Zoster Vaccine).
GSK Reports Findings on Coadministered RSV and Shingles Vaccines
Findings showed a noninferior immune response for both vaccines when Shingrix and Arexvy were coadministered compared with separate administration (primary endpoint). Both anti-gE antibody concentrations (immune response to Shingrix) and RSV-A and RSV-B neutralization titers increased from pre- to post-vaccination.
GSK Announces Positive Topline Data on Co-Administration of AREXVY and SHINGRIX
GSK plc (LSE/NYSE: GSK) today announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the immunogenicity, reactogenicity and safety of AREXVY (Respiratory Syncytial Virus Vaccine,
GSK shingles vaccine now available in Malaysia
GlaxoSmithKline Pharmaceutical Sdn Bhd (GSK) today announced the launch of its Herpes Zoster vaccine, Shingrix (MAL24056002ARZ), also known as Recombinant Zoster Vaccine, Adjuvanted (RZV) in Malaysia for the prevention of shingles (herpes zoster,
GSK Shingles Vaccine in Malaysia: Here’s What You Need to Know
GSK has launched it's Shingles vaccine in Malaysia and here's all you need to know about it. From what it is, to the side effects, for whom and where to get it.
GSK Reports Positive Data From Co-administration Of RSV And Shingles Vaccines
GSK plc (GSK, GSK.L) announced positive topline data from the phase 3 trial in adults 50 years and older evaluating the
GSK's RSV, Shingles vaccines show on-par immune response in joint trial
(Reuters) -British drugmaker GSK said on Wednesday administration of its respiratory syncytial virus (RSV) vaccine and shingles shot together generated the same immune response in a late-stage trial as separate adminstration of the vaccines.
GSK Sees Positive Results in Trial of Combination RSV, Shingles Vaccine
GSK recorded positive topline data in a late stage trial of its respiratory syncytial virus vaccine combined with a shingles vaccine in treating adults 50 years and older. The British pharma giant said Wednesday a Phase 3 study evaluating RSV vaccine Arexvy co-administered with Shingrix met the primary endpoint,
GSK posts late-stage trial win for co-administered RSV and shingles vaccines
GSK (NYSE:GSK) announced Wednesday that its Arexvy vaccine for respiratory syncytial virus (RSV) and its Shingrix vaccine for shingles reached the main goal in a Phase 3 trial when they were co-administered in adults aged 50 and older.
GSK's RSV vaccine meets main goal when co-administered with shingles shot
British drugmaker GSK said on Wednesday its respiratory syncytial virus (RSV) vaccine, when given together with its shingles shot, met the main goal of a late-stage trial in adults over 50 years of age.
pharmaphorum7y
GSK files shingles vaccine in US
GlaxoSmithKline has filed its Shingrix shingles vaccine in the US ... also known as herpes zoster, than Merck & Co's rival, Zostavax. It is a non-live, recombinant vaccine to help prevent ...
bernama3d
Shingles May Cause Long-Term Pain In Older People – Expert
PHN is characterised by pain lasting from three months to several years after the rash subsides, and it is also the most ...
dermatologyadvisor6d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50 Years or Older
The risk for incident gout following RZV exposure was not increased among adults aged 50 years or older, according to study findings.
New shingles vaccine could cut dementia risk by 25%, study suggests
One possibility is that infection with the Herpes zoster virus – shingles ... immune system are offered a vaccine.
TAG24 NEWS on MSN1mon
Shingles vaccine can delay onset of dementia, says study
“One possibility is that infection with the Herpes zoster virus (shingles ... immune system are offered a vaccine.
Renal & Urology News7d
No Increased Risk for Incident Gout After RZV Exposure Among Adults Aged 50+
Among the 461,323 individuals who received at least 1 RZV dose, 1264 experienced new-onset gout within 60 days postvaccination; 302 patients were determined to have incident cases of gout, with no ...